Blog

Leading the Way in Effective Drug Development

Adobe Stock 436772841
Apr 26, 2022

Open-Source AI Platforms: Driving Success through Diversity

Digital biomarkers can open a world of possibilities in understanding the nuances of a patient’s behavior and response to treatment. Rather than relying on subjective perceptions of how a patient is responding, digital biomarkers treat patient observation more like an engineering problem.

Man Speaking With Patient Minimized
Apr 13, 2022

Why open-source AI platforms are the future of patient health tracking in clinical trials

Imagine you’ve just been diagnosed with cancer and you’re enrolled in a clinical trial for a promising new drug. You notice that after chemotherapy you struggle with occasional fatigue. Yet, whenever you visit your doctor every couple of weeks, you feel fine. This is not only a frustrating experience for patients, but it can also compromise the safety data in a clinical trial.

Ny data
Mar 24, 2022

From Black Box to Transparency: Pulling the Curtain Back on Machine Learning

The introduction of Good Machine Learning Practices (GMLP) and increasing buzz around the need for transparency and standardization of machine learning (ML) are significant steps to encourage adoption and trust in these tools across the healthcare industry.

Digital Tech
Mar 07, 2022

Good Machine Learning Practice: The First Step Toward Transparency & Trust

Machine learning (ML) innovation in healthcare is growing, and the oversight on its development should keep pace to ensure it’s developed in a scientifically sound, safe way. Just as the FDA requires detailed ingredients on the side of cereal boxes to help consumers make informed health decisions, the same transparency should apply to the ML technology our patients and clinicians use every day to make informed care decisions.

Company 3
Feb 22, 2022

Mitigating Bias in AI: Holding Innovation to a Higher Standard

When it comes to building equitable, quality AI, prioritizing diverse data sets needs to be embedded in a developer’s DNA – rather than a “nice to have,” it should be a deliberate framework in which AI is built.

Adobe Stock 436772841
Feb 01, 2022

Why Diversity is one of AiCure’s Founding Principles

AI has great potential to transform drug development and patient care as we know it – from elevating a clinical trial’s data to speed up research, to supporting clinical decision-making to drive confident care.